Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone

NCT02445976 is registered in ClinicalTrials.gov with Innocrin Pharmaceutical as lead sponsor.

NCT NCT02445976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02445976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone
Lead sponsor
Innocrin Pharmaceutical
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2015
Completion date
January 31, 2019
Enrollment
197 (estimated)
Sites
21

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer